Alzheimer's Disease Detection Through Whole-Brain 3D-CNN MRI
The projected burden of dementia by Alzheimer's disease (AD) represents a looming healthcare crisis as the population of most countries grows older. Although there is currently no cure, it is possible to treat symptoms of dementia. Early diagnosis is paramount to the development and success of...
Saved in:
Published in | Frontiers in bioengineering and biotechnology Vol. 8; p. 534592 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
30.10.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The projected burden of dementia by Alzheimer's disease (AD) represents a looming healthcare crisis as the population of most countries grows older. Although there is currently no cure, it is possible to treat symptoms of dementia. Early diagnosis is paramount to the development and success of interventions, and neuroimaging represents one of the most promising areas for early detection of AD. We aimed to deploy advanced deep learning methods to determine whether they can extract useful AD biomarkers from structural magnetic resonance imaging (sMRI) and classify brain images into AD, mild cognitive impairment (MCI), and cognitively normal (CN) groups. We tailored and trained Convolutional Neural Networks (CNNs) on sMRIs of the brain from datasets available in online databases. Our proposed method, ADNet, was evaluated on the CADDementia challenge and outperformed several approaches in the prior art. The method's configuration with machine-learning domain adaptation, ADNet-DA, reached 52.3% accuracy. Contributions of our study include devising a deep learning system that is entirely automatic and comparatively fast, presenting competitive results without using any patient's domain-specific knowledge about the disease. We were able to implement an end-to-end CNN system to classify subjects into AD, MCI, or CN groups, reflecting the identification of distinctive elements in brain images. In this context, our system represents a promising tool in finding biomarkers to help with the diagnosis of AD and, eventually, many other diseases. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Biomaterials, a section of the journal Frontiers in Bioengineering and Biotechnology Edited by: Concetto Spampinato, University of Catania, Italy Reviewed by: Amit Alexander, National Institute of Pharmaceutical Education and Research, India; Carmelo Pino, University of Catania, Italy Some data used in the preparation of this article were obtained from the Australian Imaging Biomarkers and Lifestyle flagship study of aging (AIBL) funded by the Commonwealth Scientific and Industrial Research Organization (CSIRO) which was made available at the ADNI database Some data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (https://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report |
ISSN: | 2296-4185 2296-4185 |
DOI: | 10.3389/fbioe.2020.534592 |